Goldman Sachs Reiterates Top Rating on Cerner (CERN) After Health Conference

Goldman Sachs reiterated its Conviction Buy List rating and $80 price target on Cerner (NASDAQ: CERN) following the company's annual Health Conference user forum.

Takeaways from the conference: 1. checks with Cerner customers suggest continued robust activity within the US HCIT market; 2. Cerner customers reported satisfaction with implementations; 3. Upcoming Powerchart mobile (targeted 3Q 2012) has the potential to be a game changer for physician adoption; 4. see the Healthe Intent platform developing into an additional industry with initial revenues to come as early as 2012; 5. The Cerner Research Platform (electronic data capture and clinical trial enrollment) is gaining internal emphasis.

For more ratings news on Cerner click here and for the rating history of Cerner click here.

Shares of Cerner closed at $69.32 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Goldman Sachs Positive on SanDisk (SNDK): 'We expect the stock to hold its gains'
• Yeti Holdings Inc. (YETI) PT Raised to $56 at Raymond James
• Cantor Fitzgerald Reiterates Overweight Rating on Enovix Corporation (ENVX)